
GRK2 modulator reduces fat mass while building muscle
Atrogi has revealed positive data from a human trial for its lead candidate ATR-258, a first-in-class small molecule oral GRK2-biased β2-adrenergic modulator. ATR-258 is designed to target skeletal muscle through a novel GRK2-biased signalling mechanism, with the goal of improving body composition by reducing fat mass while… Read More



